<div id="readability-page-1"><p>In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Rani Therapeutics Holdings, with a price target of <span id="expert-recommendation-target">$11.00</span>.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>According to TipRanks, Folkes is an analyst with an average return of <span>-1.2%</span> and a 40.33% success rate. Folkes covers the Healthcare sector, focusing on stocks such as MannKind, Achieve Life Sciences, and Eupraxia Pharmaceuticals.</p> <p>Currently, the analyst consensus on Rani Therapeutics Holdings is a Strong Buy with an average price target of $10.00.</p></div>

RANI

<p>H.C. Wainwright analyst Brandon Folkes has maintained a Buy rating for Rani Therapeutics Holdings (RANI), setting a price target of $11.00. The consensus among analysts is a Strong Buy with an average price target of $10.00. Folkes has an average return of -1.2% and a success rate of 40.33%, covering the Healthcare sector.</p>

H.C. Wainwright Sticks to Its Buy Rating for Rani Therapeutics Holdings (RANI)